New Two-Pronged attack on Tough-to-Treat skin cancer
NCT ID NCT06940739
Summary
This study is testing a new, modified drug called IOV-3001 in combination with a personalized cell therapy (lifileucel) for people with advanced melanoma that has spread or cannot be removed by surgery. The main goals are to find a safe dose and see how well the body handles the new drug. It is for adults whose cancer has gotten worse after standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Greenslopes Private Hospital
RECRUITINGGreenslopes, Queensland, 4120, Australia
-
SCRI Oncology Partners- Denver
RECRUITINGDenver, Colorado, 80218, United States
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
-
UNC Hospitals, The University of North Carolina at Chapel Hill
RECRUITINGChapel Hill, North Carolina, 27514, United States
Conditions
Explore the condition pages connected to this study.